Update information on human P450s

Drug Metabolism Reviews

Volumn 34, Issue 1-2, 2002, Pages 7-15

  Guengerich, F Peter ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450;

CATALYSIS; CHEMICAL REACTION; DRUG METABOLISM; ENZYME SUBSTRATE; GENE DUPLICATION; GENE MUTATION; GENETIC POLYMORPHISM; HYDROXYLATION; LIVER MICROSOME; NUCLEOTIDE SEQUENCE; REVIEW;

CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; POLYMORPHISM, GENETIC; TERMINOLOGY;

EID: 0036227791     PISSN: 03602532     EISSN: None     Source Type: Journal    
DOI: 10.1081/DMR-120001386     Document Type: Review

References (55)

1. Enzymology of human liver cytochromes P-450
2. Drug and fatty acid hydroxylation by solubilized human liver microsomal cytochrome P-450: Phospholipid requirement
3. Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism
4. Debrisoquine-type polymorphism of drug oxidation: Purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation
5. Debrisoquine/sparteine-type polymorphism of drug oxidation: Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol
6. Purification of a desmethylimipramine and debrisoquine hydroxylating cytochrome P-450 from human liver
7. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism
8. Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction
9. Hepatic metabolism of tolbutamide: Characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition
10. Purification and characterization of human liver microsomal cytochrome P-450 2A6
11. Accessibility of cytochrome P450 in microsomal membranes: Inhibition of metabolism by antibodies to cytochrome P450
12. Aryl hydrocarbon hydroxylase is inhibited by antibody to rat liver cytochrome P-450
13. Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs using antibodies raised to the analogous rat enzyme
14. Debrisoquine 4-hydroxylase: Characterization of a new P450 gene subfamily, regulation, chromosomal mapping, and molecular analysis of the DA rat polymorphism
15. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver Microsomes
16. Isolation and sequence determination of a cDNA clone related to human cytochrome P-450 nifedipine oxidase
17. Separation and characterization of highly purified forms of liver microsomal cytochrome P-450 from rats treated with polychlorinated biphenyls, phenobarbital, and 3-methylcholanthrene
18. Multiple forms of cytochrome P-450: Resolution and purification of rabbit liver aryl hydrocarbon hydroxylase
19. Purification and characterization of liver microsomal cytochromes P-450: Electrophoretic, spectral, catalytic, and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or β-naphthoflavone
20. Purified liver microsomal cytochrome P-450: Separation and characterization of multiple forms
21. C21 steroid side chain cleavage enzyme for porcine adrenal microsomes: Purification and characterization of the 17a-hydroxylase/c17,20-lyase cytochrome P-450
22. Purification and characterization of human placental aromatase cytochrome P-450
23. A new method for sequencing DNA
24. DNA sequencing with chain-terminatiing inhibitors
25. Differences in activation of heterocyclic aromatic amines by rat and human liver microsomes and by rat and human cytochromes P450 1A2
26. Comparisons of catalytic selectivity of cytochrome P450 subfamily members from different species
27. Determining the best animal model for human cytochrome P450 activities: A comparison of mouse, rat, rabbit, dog, micropig, monkey and man
28. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes
29. Antipeptide antibodies against overlapping sequences differentially inhibit human CYP2D6
30. Inhibitory anti-peptide antibody against human CYP3A4
31. Inhibitory monoclonal antibodies to human cytochrome P450 1A2: Analysis of phenacetin O-deethylation in human liver
32. Eight inhibitory monoclonal antibodies define the role of individual P-450s in human liver microsomal diazepam 7-ethoxycoumarin, and imipramine metabolism
33. Enzyme inhibition and stimulation
34. cDNA-expressed human cytochrome P450s: A new age of molecular toxicology and human risk assessment
35. Baculovirus expression of bovine cytochrome P450c17 in Sf9 cells and comparison with expression in yeast, mammalian cells, and E. coli
36. New applications of bacterial systems to problems in toxicology
37. Purification of recombinant human cytochrome P450 enzymes expressed in bacteria
38. Drug metabolism by Escherichia coli expressing human cytochromes P450
39. Functional co-expression of CYP2D6 and human NADPH-cytochrome P450 reductase in Escherichia coli
40. Coexpression of a human P450 (CYP3A4) and P450 reductase generates a highly functional monooxygenase system in Escherichia coli
41. Kinetics of cytochrome P450 2E1-catalyzed oxidation of ethanol to acetic acid via acetaldehyde
42. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity
43. m and V/K in enzyme kinetics
44. HLA-linked congenital adrenal hyperplasia results from a defective gene encoding a cytochrome P-450 specific for steroid 21-hydroxylation
45. Effects of individual mutations in the P-450 (C21) pseudogene on the P-450 (C21) activity and their distribution in the patient genomes of congenital steroid 21-hydroxylase deficiency
46. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine
47. Genetic association between sensitivity to warfarin and Expression of CYP2C9*3
48. Characterization of an in vitro model for assessing polymorphic metabolism by CYP2C9: Involvement in the mechanism of deficient losartan metabolism
49. coh substrate specificity by mutation of a single amino-acid residue
50. Hybrid cytochromes P-450 identify a substrate binding domain in P-450IIC5 and P-450IIC4
51. Selection and characterization of human cytochrome P450 1A2 mutants with altered catalytic properties
52. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans
53. Contribution of mutations in the cytochrome P450 14 -demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans
54. Genetic metabolic polymorphisms and the risk of cancer: A review of the literature